A Two Part Randomized, Open-Label Phase I Safety and Pharmacokinetic Evaluation of Gel and Ovule Formulations of TOL-463 (Intravaginal Therapy) in 18-45 Year Old Healthy Female Subjects and Women With Vaginitis
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 25 Oct 2013
At a glance
- Drugs TOL 463 (Primary)
- Indications Bacterial vaginosis; Vulvovaginal candidiasis
- Focus Adverse reactions
- 25 Oct 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 25 Oct 2013 Planned end date changed from 1 Jun 2013 to 1 Jan 2014 as reported by ClinicalTrials.gov.
- 01 Apr 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.